Clinical Trial Update: AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms [Phase 3]

View source ↗

Summary

Phase 3 clinical trial AVAJAK compares apixaban or rivaroxaban with aspirin for primary prevention of thromboembolic events in patients with JAK2V617F-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera
• Prefibrotic Early Primary Myelofibrosis

Drugs mentioned

• Apixaban (apixaban)
• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University Hospital, Brest | Conditions: Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Status: RECRUITING